Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

General Drug Use-Result Study of Evusheld Intramuscular Injection Set (Treatment and Prevention of Symptomatic Disease Caused by SARS-CoV-2 Infection)

NCT05687877 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05687877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05687877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
General Drug Use-Result Study of Evusheld Intramuscular Injection Set (Treatment and Prevention of Symptomatic Disease Caused by SARS-CoV-2 Infection)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 6, 2023
Completion date
January 20, 2025
Enrollment
366 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection